AbbVie Inc. vs The Procter & Gamble Company: Strategic Comparison

This in-depth comparison examines AbbVie Inc. and The Procter & Gamble Company across revenue, market value, business model, competitive positioning, and long-term growth strategy. Whether you are researching AbbVie Inc. on its own, evaluating The Procter & Gamble Company, or weighing the two companies side by side, the breakdown below highlights where each company leads and where the gap between AbbVie Inc. and The Procter & Gamble Company is widest.

On the headline numbers, AbbVie Inc. reports annual revenue of $61.2B against $84.3B for The Procter & Gamble Company, while their respective market capitalizations stand at $451.5B and $390.0B. AbbVie Inc. is headquartered in United States and The Procter & Gamble Company operates from United States, and those different home markets shape how each company competes.

AbbVie Inc.: AbbVie began as the separated pharmaceutical arm of Abbott Laboratories and became one of the world's largest biopharma companies by using Humira cash flow to build a broader portfolio. The company now presents itself as a diversified specialty-medicine platform rather than a single-product story.

The Procter & Gamble Company: P&G does not just sell household products; it helped invent the operating system for modern consumer goods. The 1931 brand management model, the proof-led advertising style of Ivory, the technical innovation behind Tide and Pampers, and the focused brand portfolio all still shape how the company competes.

AbbVie Inc. and The Procter & Gamble Company pursue distinct approaches to generating revenue, and understanding how each company operates is the foundation of any fair comparison between AbbVie Inc. and The Procter & Gamble Company.

AbbVie Inc. business model: AbbVie earns revenue from patented and specialty medicines sold globally through healthcare systems, insurers, distributors, specialists, hospitals, and aesthetics providers. Immunology is the largest segment, supported by neuroscience, oncology, aesthetics, eye care, and other therapeutics.

The Procter & Gamble Company business model: P&G makes money by selling branded daily-use consumer products across fabric care, home care, baby care, feminine care, family care, beauty, grooming, and health care. The model depends on product superiority, marketing, retail execution, premiumization, productivity, and repeat purchase.

The durability of a company's moat often decides long-term winners. Here is how the competitive advantages of AbbVie Inc. stack up against those of The Procter & Gamble Company.

AbbVie Inc. competitive advantage: AbbVie's advantage comes from deep immunology scale, specialist sales relationships, strong cash flow, global clinical and regulatory capabilities, and a portfolio led by Skyrizi, Rinvoq, Botox, Vraylar, Imbruvica, Venclexta, and Elahere.

The Procter & Gamble Company competitive advantage: P&G advantage is the combination of trusted brands, R&D, retail execution, manufacturing scale, category management, and a portfolio concentrated in daily-use categories where repeat purchase matters.

Future prospects matter as much as current results. The growth strategies below explain how AbbVie Inc. and The Procter & Gamble Company each plan to expand from here.

AbbVie Inc. growth strategy: AbbVie's growth strategy is to expand indications for Skyrizi and Rinvoq, defend Botox and aesthetics, invest in neuroscience and oncology, use targeted acquisitions to add late-stage assets, and maintain disciplined cash generation after Humira's decline.

The Procter & Gamble Company growth strategy: P&G strategy centers on product superiority, brand investment, productivity, digital commerce, supply-chain efficiency, portfolio focus, and selective reinvention of the company for the next consumer goods cycle.

A closer look at the financial trajectory of AbbVie Inc. and The Procter & Gamble Company rounds out the comparison.

AbbVie Inc.: AbbVie generated $61.160 billion in FY2025 net revenue, up 8.6% on a reported basis, with immunology contributing $30.406 billion. Q1 2026 revenue reached $15.002 billion, showing continued growth after the Humira patent cliff as Skyrizi and Rinvoq scaled.

The Procter & Gamble Company: P&G reported $84.284 billion of FY2025 net sales, compared with $84.039 billion in FY2024 and $82.006 billion in FY2023. Net earnings were $15.974 billion in FY2025. P&G had approximately 109,000 employees as of June 30, 2025.